Group III: claims 1-3, drawn to a pharmaceutical preparation comprising RNA

analogs, more specifically RNA aptamers, further comprising an activator

for a plasma coagulation factor, classified in class 514, subclass 44

Group IV: claim 4, drawn to a method for promoting coagulation comprising

administering the pharmaceutical preparation, classified in class 514,

subclass 44.

Group V: claims 5-7 and 12, drawn to a pharmaceutical preparation of one or more

RNA degrading, inhibiting, or masking compounds and an activator for a

plasma fibrinolytic, classified in class 514, subclass 44.

Group VI: claims 8, 10, and 11, drawn to a diagnostic aids comprising detection of

an increased plasma RNA content compared with healthy people,

involving peptide nucleic acids, classified in class 514, subclass 44.

Group VII: claims 8, 10 and 11, drawn to a diagnostic aids comprising detection of an

increased plasma RNA content compared with healthy people, involving

ribozymes, classified in class 514, subclass 44.

Group VIII: claims 8, 10 and 11, drawn to a diagnostic aids comprising detection of an

increased plasma RNA content compared with healthy people, involving

aptamers, classified in class 514, subclass 44.

Group IX: claims 9 and 11, drawn to a diagnostic aid for quantitative or qualitative

detection of coagulation factor VII-activating protease FSAP or its

proenzyme, involving peptide nucleic acids, classified in class 514,

subclass 44.